This research underscores the importance of identifying effective markers as potential bioindicators of ICI response for SMARCA4-UT patients, thereby complementing the roles of PD-L1 expression and TMB in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.